NIH unit grants XOMA $65M to work on botulism treatment

09/10/2008 | American City Business Journals

The National Institute of Allergy and Infectious Diseases awarded XOMA a $65 million contract to develop a treatment for botulism, a potentially lethal disease caused by a neurotoxin from the bacterium Clostridium botulinum. XOMA intends to begin trials next year for its first antibody product against the disease.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Associate Manager, Regulatory Affairs
Stryker
Mahwah, NJ
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC